Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 outpatients meta-analysis

BCN PEP-CoV-2-Research group (Mitja et al. Clin Infect Dis), 2020
 
NCT04304053
RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
137/157 safety concern 14%
BCN PEP-CoV-2-Study 2 (Mitja Lancet), 2020
 
NCT04304053
RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
142/165 inconclusive 15%
COMIHY, 2020
 
NCT04340544
RCThydroxychloroquinestandard of careCOVID 19 outpatientsNA
-/- inconclusive 0%
COVID-PEP Severity (Skipper), 2020
 
NCT04308668
RCThydroxychloroquineplaceboCOVID 19 outpatientssome concern
244/247 safety concern 1% 32%
COVID-PEP Severity (Skipper), 2020
 
NCT04308668
RCThydroxychloroquinecontrolCOVID 19 outpatientssome concern
244/247 no results
PATCH-cohort 1, 2020
 
NCT04329923
RCThydroxychloroquinecontrolCOVID 19 outpatientsNA
-/- inconclusive 0%
Q-PROTECT -HCQ alone, 2020
 
NCT04349592
RCThydroxychloroquineplaceboCOVID 19 outpatientsNA
152/152 inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).